Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, announced that results of the Phase II clinical trial of Puma’s investigational drug PB272 (neratinib) for the neoadjuvant treatment of breast cancer (I-SPY2 TRIAL) will be presented in an oral presentation at the American Association for Cancer Research (AACR) Annual Meeting 2014, April 5-9, in San Diego, California. The presentation entitled “Neratinib plus Standard Neoadjuvant Therapy for High-Risk Breast Cancer: Efficacy Results from the I-SPY 2 TRIAL” will be included in the session entitled “Clinical Trials Symposium: Biomarker Driven Clinical Trials,” which will be held from 10:30 a.m. to 12:30 p.m. PDT on Monday, April 7, in Room 29 at the San Diego Convention Center.
Help employers find you! Check out all the jobs and post your resume.
